First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience

Read the FULL poster here.

AB001 is an Alpha Radioligand Therapy (ART) consisting of a PSMA-targeted small molecule radiolabeled with lead-212 (²¹²Pb).

PSMA is commonly overexpressed in prostate cancer and has become an attractive target for imaging agents and therapies
PSMA-targeted therapies using the beta-emitter Lutetium-177 (¹⁷⁷Lu) are established treatment options for patients with mCRPC
Early clinical data for alpha-emitter based therapies targeting PSMA have indicated promising anticancer activity in mCRPC, including cases unresponsive to treatment with ¹⁷⁷Lu-PSMA